- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Teva launches authorized generic version of Pfizer's Detrol LA
- State of the market: Are generic drugs approaching their peak?
- Reports: ESI may start 'price war' over new hepatitis C drugs
- Lipitor may be the first statin to switch to OTC
SILVER SPRING, Md. — The Food and Drug Administration has approved a generic drug made by Mylan for treating overactive bladder, according to agency records.
The FDA approved Mylan's tolterodine tartrate extended-release capsules in the 2-mg and 4-mg strengths.
The drug is a generic version of Pfizer's Detrol LA. Detrol LA has annual sales of about $700 million, according to published reports.